Merck & Co., Inc. (MRK) — closed signal from March 1, 2026
Partial Published before the outcome was known, scored automatically when the window closed on May 30, 2026.
Predicted vs. what happened
What happened
Reached 1% of the predicted growth at its peak, without hitting the target.
The thesis — published March 1, 2026
Merck is getting attention because recent cancer trial results and a fast FDA review raise chances of positive news soon. That can push the stock higher, especially since big investors often favor large healthcare companies in uncertain markets. The price may move up and down, so buying small amounts on calm pullbacks is safer than chasing big jumps.
Primary drivers
- Recent cancer trial results and regulatory updates can boost sentiment
- Large healthcare stocks get steady buying in uncertain markets
- A clear price zone helps plan entries and limit downside
- Because moves can be uneven, add shares gradually on pullbacks
How it played out
MRK: the 12% target was not reached
Lyra published MRK on 2026-03-01 at $123.82, with 12% expected growth toward $138.68. The thesis pointed to recent cancer trial results, regulatory updates, steady buying in large healthcare stocks, and a planned entry zone from $120 to $125. It also expected uneven moves.
Inside the window from 2026-03-01 to 2026-05-30, MRK peaked at $124 on 2026-04-09, with a 0.1% peak gain. It stayed below the target. The stock ended at $118.72. The thesis missed on price, although the peak stayed near the published entry zone.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.